Who Paid My Doc
Bianca Weinstock Guttman
Neurology Buffalo, NY Medical Doctor
NPI 1710957501 CMS profile 305262
100 High St, Buffalo, NY 14203
General payments
$287,551
Research payments
$18,796
Ownership & investment interest
$0
Research they led as principal investigator
$1,135,418
Through program year 2025, Bianca Weinstock Guttman of Buffalo, NY is reported in the CMS Open Payments database as having received $287,551 across 295 general payments and $18,796 in research payments paid to them. Separately, studies naming them as principal investigator received $1,135,418 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,818 | 9 | |
| 2024 | General | $2,228 | 5 | |
| 2024 | Research | $1,081 | 1 | |
| 2023 | General | $28,229 | 24 | |
| 2023 | Research | $1,006 | 1 | |
| 2022 | General | $31,417 | 47 | |
| 2022 | Research | $5,747 | 7 | |
| 2021 | General | $36,265 | 24 | |
| 2021 | Research | $5,292 | 4 | |
| 2020 | General | $68,433 | 44 | |
| 2020 | Research | $4,108 | 7 | |
| 2019 | General | $117,161 | 142 | |
| 2019 | Research | $1,562 | 4 |
Beside peers
- Bianca Weinstock Guttman
- Neurology median
- Middle half of Neurology
- National median
In program year 2025, general payments to Bianca Weinstock Guttman were reported at $3,818. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.
Show as a table
| Year | Bianca Weinstock Guttman | Neurology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $117,161 | $474 | $118–$2,177 | $163 |
| 2020 | $68,433 | $367 | $82–$2,309 | $114 |
| 2021 | $36,265 | $438 | $104–$2,547 | $132 |
| 2022 | $31,417 | $442 | $103–$2,388 | $149 |
| 2023 | $28,229 | $464 | $119–$2,312 | $160 |
| 2024 | $2,228 | $468 | $119–$2,323 | $164 |
| 2025 | $3,818 | $457 | $118–$2,344 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 56 drugsPart D claims
2,232
Drug cost
$3,588,742
Branded share of claims
34.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Avonex Pen (4 Pack) Interferon Beta-1a | Brand | 96 | $833,731 | |
| Avonex (4 Pack) Interferon Beta-1a | Brand | 65 | $593,905 | |
| Copaxone Glatiramer Acetate | Brand | 43 | $402,207 | |
| Rebif Rebidose Interferon Beta-1a/Albumin | Brand | 26 | $290,391 | |
| Kesimpta Pen Ofatumumab | Brand | 31 | $263,858 | |
| Tecfidera Dimethyl Fumarate | Brand | 19 | $175,541 | |
| Teriflunomide | Generic | 101 | $156,321 | |
| Glatiramer Acetate | Generic | 68 | $149,040 | |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | Brand | 54 | $121,605 | |
| Glatopa Glatiramer Acetate | Brand | 21 | $105,897 |
The 10 drugs with the highest cost, of 56 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 27 billing codesPaid by Medicare
$462,743
Medicare patients
117
Services billed
23,850
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 60% | |
| Arthritis | 42% | |
| Depression | 37% | |
| Osteoporosis | 26% | |
| Chronic kidney disease | 15% | |
| COPD | 14% | |
| Ischemic heart disease | 13% | |
| Diabetes | 12% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 21 | 6,070 | $1,377 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 17 | 41 | $27 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
319 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurology in New York
Related records
Neurology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Neurology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.